AMI Asset Management Corp Has $44.15 Million Stake in Insulet Corporation $PODD

AMI Asset Management Corp decreased its stake in shares of Insulet Corporation (NASDAQ:PODD) by 2.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 155,324 shares of the medical instruments supplier’s stock after selling 3,707 shares during the period. Insulet accounts for about 2.5% of AMI Asset Management Corp’s holdings, making the stock its 16th largest position. AMI Asset Management Corp owned about 0.22% of Insulet worth $44,149,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. True Wealth Design LLC grew its holdings in Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 72 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its holdings in Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 43 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in Insulet in the 3rd quarter valued at approximately $49,000. Quent Capital LLC acquired a new stake in Insulet in the 3rd quarter valued at approximately $49,000. Finally, Osterweis Capital Management Inc. acquired a new stake in Insulet in the 2nd quarter valued at approximately $51,000.

Insulet Price Performance

Shares of PODD stock opened at $197.78 on Tuesday. The stock has a 50 day moving average of $231.07 and a two-hundred day moving average of $278.35. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. Insulet Corporation has a 12 month low of $194.61 and a 12 month high of $354.88. The company has a market capitalization of $13.70 billion, a P/E ratio of 56.51, a P/E/G ratio of 1.18 and a beta of 1.47.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The company’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the company earned $1.15 EPS. As a group, equities analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Insider Activity at Insulet

In related news, Director Michael R. Minogue bought 2,030 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the transaction, the director directly owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.39% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Barclays reaffirmed an “underweight” rating and issued a $286.00 target price on shares of Insulet in a report on Thursday, February 19th. Raymond James Financial lowered their target price on Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. JPMorgan Chase & Co. lowered their target price on Insulet from $415.00 to $340.00 and set an “overweight” rating on the stock in a report on Thursday, February 19th. Sanford C. Bernstein lowered their target price on Insulet from $380.00 to $330.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Finally, Citigroup lowered Insulet from a “buy” rating to a “neutral” rating and lowered their target price for the company from $338.00 to $230.00 in a report on Tuesday, April 7th. Nineteen analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $339.14.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.